Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444872 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction
A Phase 1 study of Heart Failure and Kidney Disease, sponsored by Trevena.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT01444872 is a Phase 1 study of Heart Failure and Kidney Disease that has completed, run by Trevena. The registered enrollment target is 17 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01444872, a Phase 1 study of Heart Failure and Kidney Disease, has completed, sponsored by Trevena.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TRV120027 in subjects with heart failure and mild to moderate renal dysfunction.
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG TRV120027
Study Locations (4)
Florida
- Orlando Clinical Research Center - Orlando
Minnesota
- DaVita Clinical Research - Minneapolis
North Carolina
- Duke Clinical Research Unit - Durham
Tennessee
- New Orleans Center for Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01444872
The ClinicalTrials.gov registry entry for NCT01444872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Trevena, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT01444872 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01444872 about?
NCT01444872 is a clinical study titled "Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TRV120027 in subjects with heart failure and mild to moderate renal dysfunction.
What is the current status of trial NCT01444872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2011-08. Estimated completion is 2012-06.
What conditions does trial NCT01444872 study?
This clinical trial studies the following conditions: Heart Failure, Kidney Disease.
What interventions are being tested in trial NCT01444872?
The interventions under investigation include: Normal Saline (DRUG), TRV120027 (DRUG).
Who is sponsoring clinical trial NCT01444872?
This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01444872 being conducted?
This trial has 4 study locations across Florida, Minnesota, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.